Faculty - Experimental Therapeutics Ph.D. Track

Boyko Atanassov, PhD
Assistant Professor of Oncology
Department of Pharmacology and Therapeutics

Functions and regulation of deubiquitinating enzymes (USPs); Epigenetics; Regulation of gene expression, Molecular mechanism of cancer metastasis.


Dhyan Chandra, PhD
Associate Professor of Oncology
Department of Pharmacology and Therapeutics

Heat-shock proteins and cell survival, mitochondrial fragmentation and caspase activation, apoptosis signaling in cancer stem cells.


Gokul Das, PhD
Associate Professor of Oncology
Department of Pharmacology and Therapeutics

Tumor suppressor protein p53/transcriptional regulation/genomic damage, DNA repair, and cell cycle control/interaction between p53 and estrogen receptor signaling pathways.


John Ebos, PhD
Assistant Professor of Oncology
Department of Pharmacology and Therapeutics

Host- and tumor-mediated mechanisms of antiangiogenic drug resistance and their role in metastatic disease progression.


Jia Fang, PhD
Associate Professor of Oncology
Department of Pharmacology and Therapeutics

Research focuses on molecular dissection of various epigenetic mechanisms and understanding their roles in tumor progression and metastasis, with the goal of identifying novel therapeutic, diagnostic and prognostic modalities.


Michael E. Feigin, PhD
Assistant Professor of Oncology
Department of Pharmacology and Therapeutics

Exploring the noncoding genome and GPCR signaling networks driving pancreas and breast cancer pathogenesis; 3D modeling of human tumors for therapeutic and mechanistic studies.


Michael Fiandalo
Instructor

Research is focused on inhibiting the androgen metabolism enzymes that facilitate prostate cancer therapeutic resistance and prostate cancer recurrence.


Barbara Foster, PhD
Director
Experimental Therapeutics Graduate Program

Prostate cancer; transgenic mouse models; prostate cancer/bone interaction; preclinical testing of novel therapeutic approaches for prevention and treatment of prostate cancer.


David Goodrich, PhD
Member
Molecular Pharmacology and Cancer Therapeutics Graduate Program

Elucidating molecular mechanisms underlying tumor suppression by the Rb1 gene, particularly in cell cycle regulation, with the aim of targeting this pathway for cancer therapy


Elizabeth Griffiths, MD
Director
Myelodysplastic Syndrome Program

Cancer Epigenetics, Wnt biology, Acute Myeloid Leukemia


Nitai C Hait, PhD
Assistant Member
Department of Molecular and Cellular Biology

Research focuses on the role of bioactive sphingolipid metabolites, sphingosine-1-phosphate (S1P) and ceramide-1-phosphate (C1P) in cancer progression and metastasis, with the aim of targeting these signaling pathways for cancer therapy.


Pamela Hershberger, PhD
Director
Department of Pharmacology and Therapeutics Faculty Writing Group

Exploiting nuclear hormone receptor signaling pathways in the prevention and treatment of lung cancer; drug resistance in lung cancer.


Steven Hochwald, MD, MBA, FACS
Chief
Gastrointestinal/Endocrine Surgery

Research involves showing the direct interaction between FAK and IGF-1R signal transduction proteins in mammalian and cancer cells. Has patented the invention of novel small molecules that disrupt FAK and IGF-1R protein interactions.


Wendy Huss, PhD
Co-Leader
GU-Disease Site Research Group

Targeting the prostate tumor stem cell therapeutically in effort to eliminate the source of recurrent prostate cancer.


Candace S. Johnson, PhD
President & CEO
Roswell Park Comprehensive Cancer Center

Drug development of novel agents; preclinical tumor models; mechanistic studies on drugs with novel targets; steroid hormones and their potential as an antiproliferative agent and development of novel approaches in prostate cancer.


Pawel Kalinski, MD, PhD
Director
Cancer Vaccine and Dendritic Cell Therapies, Center for Immunotherapy

My research aims to develop effective immune therapies of cancer, capable of selectively activating effector and memory-type CTLs and Th1 cells and promoting their selective accumulation in tumor tissues.


Fengzhi Li, PhD
Associate Professor of Oncology
Department of Pharmacology and Therapeutics

Mechanism of anti-apoptotic protein function and regulation in cancer cells.


Jonathan F. Lovell, PhD
Associate Professor of Biomedical Engineering
Department of Biomedical Engineering
Jacobs School of Medicine & Biomedical Sciences

Current cancer research focus involves light-activated drug delivery and liposome-based vaccine adjuvants.


Donald E. Mager, PharmD, PhD, FCP
Professor and Vice Chair
Department of Pharmaceutical Sciences
University at Buffalo School of Pharmacy & Pharmaceutical Sciences

Development of models of pharmacological target-mediated drug disposition and dynamics, and the experimental validation of the primary determinants of PK/PD profiles of drugs that exhibit such phenomena


James Mohler, MD
Chief
Inter-Institutional Academics

Activities have focused upon the role for the androgen receptor in prostate cancer recurrence after androgen deprivation therapy and racial differences in prostate cancer aggressiveness.


Ravindra Pandey, PhD
Director
Pharmaceutical Chemistry

Development of “Multifunctional Agents” for tumor imaging and therapy.


Beth Pflug, PhD
Associate Member
Clinical Research

The laboratory focuses on understanding tumor signaling and growth regulation in prostate cancer and uses this information to identify novel therapeutic and imaging targets for this disease.


Mukund Seshadri, DDS, PhD
Chair
Department of Oral Oncology

Research is focused on the use of advanced imaging techniques such as magnetic resonance imaging, (MRI), computed tomography (CT) and optical molecular imaging techniques in preclinical and clinical studies.


Robert Straubinger, PhD
Professor
Department of Pharmaceutical Sciences, State University of New York at Buffalo

Cell biology and biophysics of membranes and membrane function; use of liposomal drug carriers to improve the efficacy of cancer therapeutics.


Dean Tang, PhD
Chair
Department of Pharmacology and Therapeutics

Understanding the molecular and cellular basis of tumor cell heterogeneity and developing novel therapeutics targeting cancer stem cells.


Xinjiang Wang, PhD
Associate Professor
Department of Pharmacology and Therapeutics

Identification of regulators of tumor cell growth control through biochemical and cell-based approaches; development of targeted cancer therapeutics.


Anna Woloszynska, PhD
Assistant Professor of Oncology
Department of Pharmacology and Therapeutics

Research is focused on the role of genetic and epigenetic changes in bladder and prostate cancer in order to decipher the molecular landscape of the diseases, and to point to novel strategies for improved treatment. Research is also conducted in the area of prostate cancer racial health disparities; specifically, the role of DNA methylation and vitamin D deficiency in aggressiveness of prostate cancer among African-American men.


Yue Wu, PhD
Assistant Professor of Oncology
Department of Urology

Research is focused on tumor microenvironment and molecular signaling in prostate cancer.


Yuesheng Zhang, MD, PhD
Member and Professor of Oncology
Department of Pharmacology and Therapeutics

Non-enzymatic functions of prolidase, modulation of plasma protein degradation for development of protein therapeutics and disease biomarkers, EGFR- and HER2-directed cancer drug discovery and development.